OpenURL Connection Search

Select item for more details and to access through your institution.

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Published in:
2021
By:
- Chan, Arlene;
- Moy, Beverly;
- Mansi, Janine;
- Ejlertsen, Bent;
- Holmes, Frankie Ann;
- Chia, Stephen;
- Iwata, Hiroji;
- Gnant, Michael;
- Loibl, Sibylle;
- Barrios, Carlos H.;
- Somali, Isil;
- Smichkoska, Snezhana;
- Martinez, Noelia;
- Garcia-Alonso, Mirta;
- Link, John S.;
- Mayer, Ingrid A.;
- Cold, Søren;
- Morales Murillo, Serafin;
- Senecal, Francis;
- Inoue, Kenichi
Publication type:
journal article
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Published in:
2016
By:
- Gómez, Henry L.;
- Neciosup, Silvia;
- Tosello, Célia;
- Mano, Max;
- Bines, José;
- Ismael, Gustavo;
- Santi, Patrícia X.;
- Pinczowski, Hélio;
- Nerón, Yeni;
- Fanelli, Marcello;
- Fein, Luis;
- Sampaio, Carlos;
- Lerzo, Guillermo;
- Capó, Adolfo;
- Zarba, Juan J.;
- Blajman, César;
- Varela, Mirta S.;
- Martínez-Mesa, Jeovany;
- Werutsky, Gustavo;
- Barrios, Carlos H.
Publication type:
journal article
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2023, v. 15, p. 1, doi. 10.1177/17588359231178125
By:
- Slamon, Dennis J.;
- Fasching, Peter A.;
- Hurvitz, Sara;
- Chia, Stephen;
- Crown, John;
- Martín, Miguel;
- Barrios, Carlos H.;
- Bardia, Aditya;
- Im, Seock-Ah;
- Yardley, Denise A.;
- Untch, Michael;
- Huang, Chiun-Sheng;
- Stroyakovskiy, Daniil;
- Xu, Binghe;
- Moroose, Rebecca L.;
- Loi, Sherene;
- Visco, Frances;
- Bee-Munteanu, Valerie;
- Afenjar, Karen;
- Fresco, Rodrigo
Publication type:
Article
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Published in:
2018
By:
- Wu, Yi-Long;
- Sequist, Lecia V;
- Tan, Eng-Huat;
- Geater, Sarayut L;
- Orlov, Sergey;
- Zhang, Li;
- Lee, Ki Hyeong;
- Tsai, Chun-Ming;
- Kato, Terufumi;
- Barrios, Carlos H;
- Schuler, Martin;
- Hirsh, Vera;
- Yamamoto, Nobuyuki;
- O'Byrne, Kenneth;
- Boyer, Michael;
- Mok, Tony;
- Peil, Barbara;
- Märten, Angela;
- Chih-Hsin Yang, James;
- Paz-Ares, Luis
Publication type:
journal article
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Published in:
NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00328-3
By:
- Weis, Luiza N.;
- Tolaney, Sara M.;
- Barrios, Carlos H.;
- Barroso-Sousa, Romualdo
Publication type:
Article
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Published in:
2019
By:
- Chia, Stephen K. L.;
- Martin, Miguel;
- Holmes, Frankie A.;
- Ejlertsen, Bent;
- Delaloge, Suzette;
- Moy, Beverly;
- Iwata, Hiroji;
- von Minckwitz, Gunter;
- Mansi, Janine;
- Barrios, Carlos H.;
- Gnant, Michael;
- Tomašević, Zorica;
- Denduluri, Neelima;
- Šeparović, Robert;
- Kim, Sung-Bae;
- Jakobsen, Erik Hugger;
- Harvey, Vernon;
- Robert, Nicholas;
- Smith II, John;
- Harker, Graydon
Publication type:
journal article
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Published in:
2017
By:
- Musolino, Antonino;
- Campone, Mario;
- Neven, Patrick;
- Denduluri, Neelima;
- Barrios, Carlos H.;
- Cortes, Javier;
- Blackwell, Kimberly;
- Soliman, Hatem;
- Kahan, Zsuzsanna;
- Bonnefoi, Hervé;
- Squires, Matthew;
- Zhang, Yong;
- Deudon, Stephanie;
- Shi, Michael M.;
- André, Fabrice
Publication type:
journal article
Evaluation of an Implantable Venous Access System in a General Oncology Population.
Published in:
Oncology, 1992, v. 49, n. 6, p. 474, doi. 10.1159/000227095
By:
- Barrios, Carlos H.;
- Zuke, Jeffrey E.;
- Blaes, Barbara;
- Hirsch, John D.;
- Lyss, Alan P.
Publication type:
Article
Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Published in:
Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 11, p. 693, doi. 10.1177/1758834017728928
By:
- Reinert, Tomás;
- Barrios, Carlos H.
Publication type:
Article
Optimal management of hormone receptor positive metastatic breast cancer in 2016.
Published in:
Therapeutic Advances in Medical Oncology, 2015, v. 7, n. 6, p. 304, doi. 10.1177/1758834015608993
By:
- Reinert, Tomas;
- Barrios, Carlos H.
Publication type:
Article
Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023.
Published in:
Ecancermedicalscience, 2024, v. 18, n. 1676-1753, p. 1, doi. 10.3332/ecancer.2024.1698
By:
- Resende, Heloisa;
- Arai, Roberto J.;
- Barrios, Carlos H.;
- Schwyter, Fernanda;
- Teich, Nelson L. S.;
- Gomes, Andre;
- Dallari, Analluza B.;
- Bonilha, Laís A. S.;
- Souza, Claudiosvam M. A.;
- Francisco, Fernando R.;
- Munhoz, Rodrigo R.;
- Werutsky, Gustavo;
- Madi, Marisa;
- Fernandes, Paulo;
- Figueiredo, Jose M.;
- Fedozzi, Fabio;
- Arruda, Lilian;
- Aguiar, Vinícius Q.;
- Melo, Andreia C.
Publication type:
Article
Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023.
Published in:
Ecancermedicalscience, 2024, v. 18, n. 1675-1705, p. 1, doi. 10.3332/ecancer.2024.1698
By:
- Resende, Heloisa;
- Arai, Roberto J.;
- Barrios, Carlos H.;
- Schwyter, Fernanda;
- Teich, Nelson L. S.;
- Gomes, Andre;
- Dallari, Analluza B;
- Bonilha, Laís A. S.;
- Souza, Claudiosvam M. A.;
- Francisco, Fernando R.;
- Munhoz, Rodrigo R.;
- Werutsky, Gustavo;
- Madi, Marisa;
- Fernandes, Paulo;
- Figueiredo, Jose M.;
- Fedozzi, Fabio;
- Arruda, Lilian;
- Aguiar, Vinícius Q.;
- Melo, Andreia C.
Publication type:
Article
Clinical validation and diagnostic accuracy of 99mTc-EDDA/HYNIC-TOC compared to 111In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study.
Published in:
Ecancermedicalscience, 2023, v. 17, n. 1551-1584, p. 1, doi. 10.3332/ecancer.2023.1582
By:
- Moriguchi-Jeckel, Cristina M.;
- Madke, Rafael R.;
- Radaelli, Graciane;
- Viana, Alice;
- Nabinger, Patrícia;
- Fernandes, Bruna;
- Gössling, Gustavo;
- Berdichevski, Eduardo H.;
- Vilas, Eduardo;
- Giacomazzi, Juliana;
- Rocha, Matheus Soares;
- Borges, João Alfredo;
- Hoffmann, Elias;
- Greggio, Samuel;
- Venturin, Gianina T.;
- Barrios, Carlos H.;
- Zaffaroni, Facundo;
- Werutsky, Gustavo;
- da Costa, Jaderson C.
Publication type:
Article
Clinical implications of eSR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.
Published in:
Frontiers in Oncology, 2017, v. 7, p. 1, doi. 10.3389/fonc.2017.00026
By:
- Reinert, Tomas;
- Saad, Everardo D.;
- Barrios, Carlos H.;
- Bines, José
Publication type:
Article
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Published in:
2019
By:
- Perez, Edith A.;
- de Haas, Sanne Lysbet;
- Eiermann, Wolfgang;
- Barrios, Carlos H.;
- Toi, Masakazu;
- Im, Young-Hyuck;
- Conte, Pier Franco;
- Martin, Miguel;
- Pienkowski, Tadeusz;
- Pivot, Xavier B.;
- Burris III, Howard A.;
- Stanzel, Sven;
- Patre, Monika;
- Ellis, Paul Anthony;
- Burris, Howard A 3rd
Publication type:
journal article
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Published in:
2019
By:
- Perez, Edith A.;
- de Haas, Sanne Lysbet;
- Eiermann, Wolfgang;
- Barrios, Carlos H.;
- Toi, Masakazu;
- Im, Young-Hyuck;
- Conte, Pier Franco;
- Martin, Miguel;
- Pienkowski, Tadeusz;
- Pivot, Xavier B.;
- Burris III, Howard A.;
- Stanzel, Sven;
- Patre, Monika;
- Ellis, Paul Anthony;
- Burris, Howard A 3rd
Publication type:
journal article
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
Published in:
2019
By:
- Werutsky, Gustavo;
- Hochhegger, Bruno;
- Lopes de Figueiredo Pinto, José Antônio;
- Martínez-Mesa, Jeovany;
- Zanini, Mara Lise;
- Berdichevski, Eduardo Herz;
- Vilas, Eduardo;
- da Silva, Vinícius Duval;
- Tsukazan, Maria Teresa Ruiz;
- Vieira, Arthur;
- Fritscher, Leandro Genehr;
- Hartmann, Louise;
- Alba, Marcos;
- Sartori, Guilherme;
- Matushita, Cristina;
- Bortolotto, Vanessa;
- do Amaral, Rayssa Ruszkowski;
- Junior, Luís Carlos Anflor;
- Zaffaroni, Facundo;
- Barrios, Carlos H.
Publication type:
journal article
Towards Smart-City Implementation for Crisis Management in Fast-Growing and Unplanned Cities: The Colombian Scenario.
Published in:
Ingeniería y Ciencia, 2020, v. 16, n. 32, p. 151, doi. 10.17230/ingciencia.16.32.7
By:
- Puentes, Michael;
- Arroyo, Irene;
- Carrillo, Oscar;
- Barrios H., Carlos J.;
- Le Mouël, Frédéric
Publication type:
Article
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Published in:
Cancer (0008543X), 2012, v. 118, n. 5, p. 1252, doi. 10.1002/cncr.26440
By:
- Barrios, Carlos H.;
- Hernandez-Barajas, David;
- Brown, Michael P.;
- Lee, Se-Hoon;
- Fein, Luis;
- Liu, Jin-Hwang;
- Hariharan, Subramanian;
- Martell, Bridget A.;
- Yuan, Jinyu;
- Bello, Akintunde;
- Wang, Zhixiao;
- Mundayat, Rajiv;
- Rha, Sun-Young
Publication type:
Article
Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.
Published in:
OncoTargets & Therapy, 2016, v. 9, p. 5839, doi. 10.2147/OTT.S109445
By:
- Barrios, Carlos H.;
- Herchenhorn, Daniel;
- Chacón, Matías;
- Cabrera-Galeana, Paula;
- Sajben, Peter;
- Ke Zhang
Publication type:
Article
Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
Published in:
PLoS ONE, 2018, v. 13, n. 8, p. 1, doi. 10.1371/journal.pone.0202865
By:
- Lee, Dae Ho;
- Tsao, Ming-Sound;
- Kambartel, Karl-Otto;
- Isobe, Hiroshi;
- Huang, Ming-Shyan;
- Barrios, Carlos H.;
- Khattak, Adnan;
- de Marinis, Filippo;
- Kothari, Smita;
- Arunachalam, Ashwini;
- Cao, Xiting;
- Burke, Thomas;
- Valladares, Amparo;
- de Castro, Javier
Publication type:
Article
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Published in:
JNCI: Journal of the National Cancer Institute, 2024, v. 116, n. 5, p. 717, doi. 10.1093/jnci/djad240
By:
- Cescon, David W;
- Schmid, Peter;
- Rugo, Hope S;
- Im, Seock-Ah;
- Yusof, Mastura Md.;
- Gallardo, Carlos;
- Lipatov, Oleg;
- Barrios, Carlos H;
- Perez-Garcia, Jose;
- Iwata, Hiroji;
- Masuda, Norikazu;
- Otero, Marco Torregroza;
- Gokmen, Erhan;
- Loi, Sherene;
- Haiderali, Amin;
- Zhou, Xuan;
- Guo, Zifang;
- Nguyen, Allison Martin;
- Cortes, Javier
Publication type:
Article
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Published in:
2021
By:
- Rugo, Hope S;
- Loi, Sherene;
- Adams, Sylvia;
- Schmid, Peter;
- Schneeweiss, Andreas;
- Barrios, Carlos H;
- Iwata, Hiroji;
- Diéras, Véronique;
- Winer, Eric P;
- Kockx, Mark M;
- Peeters, Dieter;
- Chui, Stephen Y;
- Lin, Jennifer C;
- Nguyen-Duc, Anh;
- Viale, Giuseppe;
- Molinero, Luciana;
- Emens, Leisha A;
- Duc, Anh Nguyen
Publication type:
journal article
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Published in:
2021
By:
- Emens, Leisha A;
- Molinero, Luciana;
- Loi, Sherene;
- Rugo, Hope S;
- Schneeweiss, Andreas;
- Diéras, Véronique;
- Iwata, Hiroji;
- Barrios, Carlos H;
- Nechaeva, Marina;
- Nguyen-Duc, Anh;
- Chui, Stephen Y;
- Husain, Amreen;
- Winer, Eric P;
- Adams, Sylvia;
- Schmid, Peter
Publication type:
journal article
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
Published in:
2019
By:
- Lambertini, Matteo;
- Campbell, Christine;
- Bines, José;
- Korde, Larissa A;
- Izquierdo, Miguel;
- Fumagalli, Debora;
- Mastro, Lucia Del;
- Ignatiadis, Michail;
- Pritchard, Kathleen;
- Wolff, Antonio C;
- Jackisch, Christian;
- Lang, Istvan;
- Untch, Michael;
- Smith, Ian;
- Boyle, Frances;
- Xu, Binghe;
- Barrios, Carlos H;
- Baselga, José;
- Moreno-Aspitia, Alvaro;
- Piccart, Martine
Publication type:
journal article
ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
Published in:
Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00342
By:
- Reinert, Tomás;
- Ramalho, Susana;
- de Vasconcelos, Vivian Castro Antunes;
- Silva, Leonardo Roberto;
- da Silva, Ana Elisa Ribeiro;
- de Andrade, Camila Annicchino;
- Kraft, Maria Beatriz de Paula Leite;
- Coelho, Guilherme Portela;
- Mandelli, Jovana;
- Binotto, Monique;
- Cabello, Cesar;
- Paiva Silva, Geisilene Russano de;
- Bines, José;
- Barrios, Carlos H.;
- Ellis, Matthew J.;
- Graudenz, Marcia Silveira
Publication type:
Article
Enhancing global access to cancer medicines.
Published in:
2020
By:
- Cortes, Javier;
- Perez‐García, Jose Manuel;
- Llombart‐Cussac, Antonio;
- Curigliano, Giuseppe;
- El Saghir, Nagi S.;
- Cardoso, Fatima;
- Barrios, Carlos H.;
- Wagle, Shama;
- Roman, Javier;
- Harbeck, Nadia;
- Eniu, Alexandru;
- Kaufman, Peter A.;
- Tabernero, Josep;
- García‐Estévez, Laura;
- Schmid, Peter;
- Arribas, Joaquín;
- Perez-García, Jose Manuel;
- Llombart-Cussac, Antonio;
- García-Estévez, Laura
Publication type:
journal article

Found: 27

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapy.

Evaluation of an Implantable Venous Access System in a General Oncology Population.

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.

Optimal management of hormone receptor positive metastatic breast cancer in 2016.

Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023.

Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023.

Clinical validation and diagnostic accuracy of <sup>99m</sup>Tc-EDDA/HYNIC-TOC compared to <sup>111</sup>In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study.

Clinical implications of eSR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).

Towards Smart-City Implementation for Crisis Management in Fast-Growing and Unplanned Cities: The Colombian Scenario.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.

Enhancing global access to cancer medicines.